Recent studies have found that the development of a hybrid closed-loop system reduces the burden of diabetes management in patients with T1D, enables glucose-responsive insulin delivery, and protects against hypoglycemia, resulting in improved glycemic control (49–51). The gene discussed is INS; the disease is diabetes mellitus.